Lymphoid fibrosis occurs in long-term nonprogressors and persists with antiretroviral therapy but may be reversible with curative interventions

Journal of Infectious Diseases

Volumn 211, Issue 7, 2015, Pages 1068-1075

  Sanchez, Joyce L ^a   Hunt, Peter W ^b   Reilly, Cavan S ^a   Hatano, Hiroyu ^b   Beilman, Gregory J ^a   Khoruts, Alexander ^a   Jasurda, Jake S ^a   Somsouk, Ma ^b   Thorkelson, Ann ^a   Russ, Samuel ^a   Anderson, Jodi ^a   Deeks, Steven G ^b   Schacker, Timothy W ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

fibrosis; HIV; HIV controllers

Indexed keywords

ANTIRETROVIRUS AGENT; COLLAGEN;

ADULT; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CELL SIZE; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; FIBROSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNE RESPONSE; LYMPHOID FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN METABOLISM; T CELL DEPLETION; T LYMPHOCYTE SUBPOPULATION; TREATMENT DURATION; VIRUS LOAD; VIRUS REPLICATION; BIOPSY; COHORT ANALYSIS; COMPLICATION; DISEASE COURSE; DRUG EFFECTS; HIV INFECTIONS; HIV SURVIVOR; HUMAN IMMUNODEFICIENCY VIRUS 1; LONGITUDINAL STUDY; LYMPHOID TISSUE; PATHOLOGY; PHYSIOLOGY; RECTUM; VIROLOGY;

ADULT; ANTI-RETROVIRAL AGENTS; BIOPSY; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FIBROSIS; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HIV-1; HUMANS; LONGITUDINAL STUDIES; LYMPHOID TISSUE; MALE; MIDDLE AGED; RECTUM; VIRUS REPLICATION;

EID: 84927732763     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu586     Document Type: Conference Paper

References (50)

1. Estes J, Baker JV, Brenchley JM, et al. Collagen deposition limits immune reconstitution in the gut. J Infect Dis 2008; 198:456-64.
2. Schacker TW, Reilly C, Beilman GJ, et al. Amount of lymphatic tissue fibrosis in HIV infection predicts magnitude of HAART-associated change in peripheral CD4 cell count. AIDS 2005; 19:2169-71.
3. Brenchley JM, Schacker TW, Ruff LE, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004; 200:749-59.
4. Schacker TW, Nguyen PL, Martinez E, et al. Persistent abnormalities in lymphoid tissues of human immunodeficiency virus-infected patients successfully treated with highly active antiretroviral therapy. J Infect Dis 2002; 186:1092-7.
5. Plaeger SF, Collins BS, Musib R, Deeks SG, Read S, Embry A. Immune activation in the pathogenesis of treated chronic HIV disease: a workshop summary. AIDS Res Hum Retroviruses 2012; 28:469-77.
6. Hunt PW, Martin JN, Sinclair E, et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 187:1534-43.
7. Haase AT. Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. Annu Rev Immunol 1999; 17:625-56.
8. Hunt PW, Martin JN, Sinclair E, et al. Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. J Infect Dis 2011; 203:1474-83.
9. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365-71.
10. Douek DC, Roederer M, Koup RA. Emerging concepts in the immunopathogenesis of AIDS. Ann Rev Med 2009; 60:471-84.
11. Ruiz-Mateos E, Machmach K, Romero-Sanchez MC, et al. Hepatitis C virus replication in Caucasian HIV controllers. J Viral Hepat 2011; 18: e350-7.
12. Estes JD, Li Q, Reynolds MR, et al. Premature induction of an immunosuppressive regulatory T cell response during acute simian immunodeficiency virus infection. J Infect Dis 2006; 193:703-12.
13. Zeng M, Smith AJ, Wietgrefe SW, et al. Cumulative mechanisms of lymphoid tissue fibrosis and T cell depletion in HIV-1 and SIV infections. J Clin Invest 2011; 121:998-1008.
14. Estes JD, Wietgrefe S, Schacker T, et al. Simian immunodeficiency virusinduced lymphatic tissue fibrosis is mediated by transforming growth factor beta 1-positive regulatory T cells and begins in early infection. J Infect Dis 2007; 195:551-61.
15. Schacker TW, Brenchley JM, Beilman GJ, et al. Lymphatic tissue fibrosis is associated with reduced numbers of naive CD4+ T cells in human immunodeficiency virus type 1 infection. Clin Vaccine Immunol 2006; 13:556-60.
16. Schacker TW, Nguyen PL, Beilman GJ, et al. Collagen deposition in HIV-1 infected lymphatic tissues and T cell homeostasis. J Clin Invest 2002; 110:1133-9.
17. Zeng M, Southern PJ, Reilly CS, et al. Lymphoid tissue damage in HIV-1 infection depletes naive T cells and limits T cell reconstitution after antiretroviral therapy. PLoS Pathog 2012; 8:e1002437.
18. Hunt PW, Brenchley J, Sinclair E, et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008; 197:126-33.
19. Emu B, Sinclair E, Hatano H, et al. HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for longterm virus control. J Virol 2008; 82:5398-407.
20. Ferre AL, Hunt PW, McConnell DH, et al. HIV controllers with HLADRB1∗13 and HLA-DQB1∗06 alleles have strong, polyfunctional mucosal CD4+ T-cell responses. J Virol 2010; 84:11020-9.
21. Hersperger AR, Martin JN, Shin LY, et al. Increased HIV-specific CD8+ T-cell cytotoxic potential in HIV elite controllers is associated with Tbet expression. Blood 2011; 117:3799-808.
22. Hatano H, Yukl SA, Ferre AL, et al. Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers. PLoS Pathog 2013; 9:e1003691.
23. Pereyra F, Palmer S, Miura T, et al. Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters. J Infect Dis 2009; 200:984-90.
24. Armah KA, McGinnis K, Baker J, et al. HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation. Clin Infect Dis 2012; 55:126-36.
25. Baker JV, Brummel-Ziedins K, Neuhaus J, et al. HIV replication alters the composition of extrinsic pathway coagulation factors and increases thrombin generation. J Am Heart Assoc 2013; 2:e000264.
26. Baker JV, Henry WK, Neaton JD. The consequences of HIV infection and antiretroviral therapy use for cardiovascular disease risk: shifting paradigms. Curr Opin HIV AIDS 2009; 4:176-82.
27. Hsue PY, Hunt PW, Schnell A, et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS 2009; 23:1059-67.
28. Pereyra F, Lo J, Triant VA, et al. Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers. AIDS 2012; 26:2409-12.
29. Yukl SA, Boritz E, Busch M, et al. Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog 2013; 9:e1003347.
30. Saez-Cirion A, Bacchus C, Hocqueloux L, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 2013; 9:e1003211.
31. Krishnan S, Wilson EM, Sheikh V, et al. Evidence for innate immune system activation in HIV type 1-infected elite controllers. J Infect Dis 2014; 209:931-9.
32. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-96.
33. Crum-Cianflone NF, Grandits G, Echols S, et al. Trends and causes of hospitalizations among HIV-infected persons during the late HAART era: what is the impact of CD4 counts and HAART use? J Acquir Immune Defic Syndr 2010; 54:248-57.
34. Maurer T, Rodrigues LK, Ameli N, et al. The effect of highly active antiretroviral therapy on dermatologic disease in a longitudinal study of HIV type 1-infected women. Clin Infect Dis 2004; 38:579-84.
35. Posavad CM, Wald A, Kuntz S, et al. Frequent reactivation of herpes simplex virus among HIV-1-infected patients treated with highly active antiretroviral therapy. J Infect Dis 2004; 190:693-6.
36. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370:59-67.
37. Baker JV, Neuhaus J, Duprez D, et al. Inflammation predicts changes in high-density lipoprotein particles and apolipoprotein A1 following initiation of antiretroviral therapy. AIDS 2011; 25:2133-42.
38. Grinspoon SK, Grunfeld C, Kotler DP, et al. State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation 2008; 118:198-210.
39. Lange CG, Lederman MM, Medvik K, et al. Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection. AIDS 2003; 17:2015-23.
40. Lange CG, Valdez H, Medvik K, Asaad R, Lederman MM. CD4+ Tlymphocyte nadir and the effect of highly active antiretroviral therapy on phenotypic and functional immune restoration in HIV-1 infection. Clin Immunol 2002; 102:154-61.
41. Vigano A, Zuccotti GV, Pacei M, et al. Humoral and cellular response to influenza vaccine in HIV-infected children with full viroimmunologic response to antiretroviral therapy. J Acquir Immune Defic Syndr 2008; 48:289-96.
42. Lederman HM, Williams PL, Wu JW, et al. Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected patients with severe CD4+ cell depletion. J Infect Dis 2003; 188:1794-803.
43. Lederman MM, Connick E, Landay A, et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis 1998; 178:70-9.
44. Lohse N, Hansen AB, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann intern Med 2007; 146:87-95.
45. Fletcher CV, Staskus K, Wietgrefe SW, et al. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci USA 2014; 111:2307-12.
46. Hatano H, Strain MC, Scherzer R, et al. Increase in 2-LTR circle after raltegravir intensification in HAART-suppressed patients with high CD4+ T cell counts: a randomized controlled trial. Presented at: 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, Georgia, 2013.
47. Buzon MJ, Massanella M, Llibre JM, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAARTsuppressed subjects. Nat Med 2010; 16:460-5.
48. Massanella M, Esteve A, Buzon MJ, et al. Dynamics of CD8 T-cell activation after discontinuation of HIV treatment intensification. J Acquir Immune Defic Syndr 2013; 63:152-60.
49. Tabb B, Morcock DR, Trubey CM, et al. Reduced inflammation and lymphoid tissue immunopathology in rhesus macaques receiving anti-tumor necrosis factor treatment during primary simian immunodeficiency virus infection. J Infect Dis 2013; 207:880-92.
50. Estes JD, Reilly C, Trubey CM, et al. Antifibrotic therapy in SIV infection preserves CD4 T cell populations and improves immune reconstitution with antiretroviral therapy. J Infect Dis 2015; 211:744-54.